This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
April 8, 2014 /PRNewswire/ -- GE Healthcare, a unit of General Electric Company (NYSE: GE), today announced that it received U.S. FDA 510(k) clearance of its Q.Clear^ technology – technology that can provide up to two times improvement in both quantitative accuracy and image quality in PET/CT imaging. This is an innovative new tool for clinicians across the entire care continuum including diagnosis, staging, treatment planning, and treatment assessment.
Over the last decade, PET image reconstruction technology has been designed to provide better image quality, reduced acquisition time and lower injected dose. Current PET iterative reconstruction technologies, such as Time of Flight (TOF) and OSEM, force a compromise between image quality and quantitation. GE Healthcare's new Q.Clear technology shows the advantage of full convergence PET imaging with no more compromise between quantitation and image quality.
"Q.Clear is a major step forward because it can give us a consistent and reliable measurement when determining whether the current course of a patient's cancer treatment is effective," said Dr.
Gustav von Schulthess, Nuclear Medicine Chair at University Hospital Zurich. "It will give the oncologist more confidence because if a change of therapy is needed, you want accurate information early on to best adjust treatment for the patient."
Clinicians not only want the ability to detect smaller lesions, but the ability to determine earlier whether the patient is responding to current treatment. Q.Clear aims to help in both areas by providing better quantitation accuracy for truly personalized medicine. Coupled with GE Healthcare's Q.Suite, which introduced the importance of eliminating variability such as respiratory motion, Q.Clear can enable clinicians to assess treatment response accurately so they can provide the best patient care.
"We know that approximately 70% of cancer patients don't always respond to their initial course of treatment," said
Steve Gray, president and CEO of GE Healthcare MICT. "If we can give clinicians an accurate, reliable, and faster tool to confirm that a change in treatment is needed, the patient will benefit greatly. For example, PET/CT can help clinicians determine whether chemotherapy is working in fewer cycles, saving patients unnecessary procedures. Q.Clear gives clinicians the ability to help make that determination."
^ Not available for sale in all regions. For countries that require CE marking, Q.Clear is not yet CE marked and cannot be placed on the market or put into service in such countries until it is made to comply with CE marking.